A phase 2 study of the efficacy and safety of muvalaplin (LY3473329) in adults with elevated Lp(a) at high risk of cardiovascular (CV) events
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
